Recent Finacing
Recent Raise
Roca Therapeutics develops small-molecule drugs targeting M2 macrophage–driven immunosuppression and resistant angiogenesis, advancing RCT001 for metastatic uveal melanoma and nominating a second candidate for neovascular glaucoma.
Focus Areas
Recent Investors
Funding round
Investors
